MITOXANTRONE REDUCED DISABILITY IN IRANIAN PATIENTS WITH MULTIPLE SCLEROSIS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

HAMZEHLOU A.; ETEMADIFAR M.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: ARCHIVES OF IRANIAN MEDICINE Year:2007 | Volume:10 | Issue:1 Page(s): 59-64

Download Full-Text

View:

360

Download:

277

Cites:

Information Journal Paper

Title

MITOXANTRONE REDUCED DISABILITY IN IRANIAN PATIENTS WITH MULTIPLE SCLEROSIS

Author(s)

HAMZEHLOU A. | ETEMADIFAR M. | Issue Writer Certificate

Keywords

MITOXANTRONE

MULTIPLE SCLEROSIS (MS)

Abstract

Background: Multiple sclerosis is a leading cause of disability in young adults. MITOXANTRONE has recently been shown to be effective in ameliorating multiple sclerosis activity and reducing the relapse rate. This study aimed to assess the efficacy of MITOXANTRONE on disease activity and decreasing relapse rate in patients with multiple sclerosis in Iran.Methods: This was a clinical trial on patients who received intravenous MITOXANTRONE, 12 mg/m2 every 3 months. The study was performed at Isfahan Multiple Sclerosis Clinics, affiliated to Isfahan University of Medical Sciences. This clinical trial was conducted from October 2003 through April 2005.One hundred and forty-seven patients with worsening relapsing-remitting and secondary progressive multiple sclerosis received MITOXANTRONE, 12 mg/m2 every 3 months. Clinical assessment was made every 3 months for one year.Results: Of the 147 patients, 129 (93 females and 36 males) could successfully complete the course of our study. A significant therapeutic effect (P<0.0001) was detected for the attack rate before and after treatment. The mean attack rate 12 months before treatment was 1.10 (SD=0.95), which reduced to 0.09 (SD=0.29) during treatment.THE Mean expanded disability status scale at the beginning of the treatment was 4.32, which declined to 3.62 (P<0.0001) after one year.Conclusion: MITOXANTRONE was generally well tolerated and reduced progression of disability and clinical exacerbation in our patients. Physicians must be careful about the complications of MITOXANTRONE especially cardiotoxicity.

Multimedia

No record.

Cites

No record.

References

No record.

Cite

APA: Copy

HAMZEHLOU, A., & ETEMADIFAR, M.. (2007). MITOXANTRONE REDUCED DISABILITY IN IRANIAN PATIENTS WITH MULTIPLE SCLEROSIS. ARCHIVES OF IRANIAN MEDICINE, 10(1), 59-64. SID. https://sid.ir/paper/280163/en

Vancouver: Copy

HAMZEHLOU A., ETEMADIFAR M.. MITOXANTRONE REDUCED DISABILITY IN IRANIAN PATIENTS WITH MULTIPLE SCLEROSIS. ARCHIVES OF IRANIAN MEDICINE[Internet]. 2007;10(1):59-64. Available from: https://sid.ir/paper/280163/en

IEEE: Copy

A. HAMZEHLOU, and M. ETEMADIFAR, “MITOXANTRONE REDUCED DISABILITY IN IRANIAN PATIENTS WITH MULTIPLE SCLEROSIS,” ARCHIVES OF IRANIAN MEDICINE, vol. 10, no. 1, pp. 59–64, 2007, [Online]. Available: https://sid.ir/paper/280163/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops